Back to Search
Start Over
Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide.
- Source :
-
Case reports in transplantation [Case Rep Transplant] 2020 Dec 12; Vol. 2020, pp. 8894922. Date of Electronic Publication: 2020 Dec 12 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Herein we present a patient that underwent a liver transplant due to primary biliary cholangitis (PBC) and after 9 years developed multiple myeloma. Following the cessation of mycophenolate mofetil and 2 weeks after lenalidomide treatment was started, the patient experienced acute cellular rejection. The patient recovered after treatment with corticosteroids, resumption of mycophenolate mofetil, and cessation of lenalidomide. Lenalidomide-associated allograft rejection has been reported in other organs. However, this is the first case report of liver rejection induced by lenalidomide.<br />Competing Interests: Dr. Gertz reports personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie and Celgene, personal fees from Research to Practice, workforce training Sanofi, speaker fees from Teva, speaker fees from Johnson and Johnson, speaker fees from Medscape, and speaker fees from DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara; Development of educational materials for i3Health.Royalties from Springer Publishing, Stock Options Aurora Bio.<br /> (Copyright © 2020 Iuliana Vaxman et al.)
Details
- Language :
- English
- ISSN :
- 2090-6943
- Volume :
- 2020
- Database :
- MEDLINE
- Journal :
- Case reports in transplantation
- Publication Type :
- Report
- Accession number :
- 33381347
- Full Text :
- https://doi.org/10.1155/2020/8894922